SAINT HELIER (dpa-AFX) - Shire plc (SHP.L, SHPG) announced that the European Commission has granted Marketing Authorization for lyophilized ONCASPAR (pegaspargase), as a component of antineoplastic combination therapy in acute lymphoblastic leukemia in pediatric patients from birth to 18 years, and in adult patients. The approval follows a positive opinion adopted by CHMP of the European Medicines Agency on October 12.
Shire expects lyophilized ONCASPAR to be available in European markets beginning in the first half of 2018.
Copyright RTT News/dpa-AFX